Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT06066424	TitlePhase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)	Fase Fase 1	Date Added 2023-10-04	Ubicación Texas, United States	Prior IO Allowed Sí	CRC-directed No	Status Reclutamiento	Drogas Cyclophosphamide, Fludarabine Phosphate, Rimiducid, TROP2-CAR-NK Cells	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06065371	TitleSacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy	Fase Fase 1	Date Added 2023-10-03	Ubicación Michigan, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas capecitabine, Sacituzumab govetican	Etiquetas MSS/ MMRp
NCT ID NCT06060704	TitleEnvafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.	Fase Fase 2	Date Added 2023-09-29	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Bevacizumab, Envafolimab, Trifluridine/Tipiracil, Avastin, Lonsurf	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06055439	TitleEstudio de fase 1/2 para evaluar CHM-2101, una terapia autóloga con células T receptoras de antígeno quimérico (CAR) de cadherina 17.	Fase Phase 1, Phase 2	Date Added 2023-09-26	Ubicación Georgia, United States Illinois, United States Pennsylvania, United States Tennessee, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06047015	TitleIrreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer	Fase Fase 1	Date Added 2023-09-21	Ubicación	Prior IO Allowed Sí	CRC-directed Sí	Status Aún no se ha contratado	Drogas	Etiquetas MSS/ MMRp
NCT ID NCT06043713	TitleCélulas T transgénicas CD8+ y CD4+ autólogas que expresan receptores de células T específicos de la mutación KRASG12V de alta afinidad (FH-A11KRASG12V-TCR) para el tratamiento de pacientes con cánceres metastásicos de páncreas, colorrectal y de pulmón de células no pequeñas con mutaciones KRAS G12V.	Fase Fase 1	Date Added 2023-09-21	Ubicación Washington, United States	Prior IO Allowed Sí	CRC-directed No	Status Activo, no recluta	Drogas Bendamustine, Cyclophosphamide, Fludarabine	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06039202	TitleEstudio de fase 2 de CA102N combinado con TAS-102 comparado con bevacizumab combinado con TAS-102 en sujetos con cáncer colorrectal metastásico recidivante y/o refractario.	Fase Fase 2	Date Added 2023-09-15	Ubicación	Prior IO Allowed Sí	CRC-directed Sí	Status Aún no se ha contratado	Drogas CA102N, TAS-102	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06039384	TitleEstudio de INCB099280 en combinación con adagrasib en adultos con tumores sólidos avanzados portadores de una mutación en KRASG12C.	Fase Fase 1	Date Added 2023-09-15	Ubicación California, United States Colorado, United States Michigan, United States Texas, United States Virginia, United States Italia España Reino Unido	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas Adagrasib, INCB099280	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06034860	TitleStudy of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types	Fase Fase 1	Date Added 2023-09-13	Ubicación California, United States Indiana, United States Missouri, United States New York, United States Virginia, United States	Prior IO Allowed Sí	CRC-directed No	Status Activo, no recluta	Drogas MT-8421, Nivolumab, Opdivo	Etiquetas MSI-H/ MMRd
NCT ID NCT06026774	TitleClinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms	Fase Fase 1	Date Added 2023-09-07	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp

Showing 41 to 50 of 299 entries